SBRT plus immunotherapy and targeted drug for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that has spread to lymph nodes in the belly area, with at least one lymph node that can be measured on a scan.
- You have 3 or fewer active tumors in the liver, and the total size of those tumors is less than 10 cm (about 4 inches).
- You are between 18 and 75 years old.
- Your liver function is good (Child-Pugh class A), and your overall health status is fair (ECOG score 0-2).
- You meet standard blood count and organ function requirements.
- You have not had abdominal radiation before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests whether adding targeted radiation therapy (SBRT) to standard systemic therapy helps people with advanced liver cancer live longer compared to systemic therapy alone.
This trial tests a combination of radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy drug (apatinib) to shrink liver cancer that cannot be removed with surgery. The goal is to make the cancer small enough for surgery later.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.